Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Operating Expenses: 2017-2018

Historic Operating Expenses for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to $6.1 million.

  • Astria Therapeutics' Operating Expenses rose 6.58% to $6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $26.4 million, marking a year-over-year decrease of 4.43%. This contributed to the annual value of $26.4 million for FY2018, which is 4.43% down from last year.
  • As of Q4 2018, Astria Therapeutics' Operating Expenses stood at $6.1 million, which was up 1.33% from $6.0 million recorded in Q3 2018.
  • In the past 5 years, Astria Therapeutics' Operating Expenses ranged from a high of $7.8 million in Q1 2017 and a low of $5.7 million during Q4 2017.
  • Its 2-year average for Operating Expenses is $6.7 million, with a median of $6.8 million in 2017.
  • Over the last 5 years, Astria Therapeutics' Operating Expenses had its largest YoY gain of 6.58% in 2018, and its largest YoY loss of 16.58% in 2018.
  • Over the past 2 years, Astria Therapeutics' Operating Expenses (Quarterly) stood at $5.7 million in 2017, then climbed by 6.58% to $6.1 million in 2018.
  • Its Operating Expenses was $6.1 million in Q4 2018, compared to $6.0 million in Q3 2018 and $6.6 million in Q2 2018.